Brandon Still, APRN
Family · Clermont, FLNPI 1215408604
Payments from drug & device makers
Across 218 payments — averaging $18.87 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AbbVie$810
- AstraZeneca$712
- Novo Nordisk$587
- Pfizer$425
- Lilly USA, LLC$350
- Exact Sciences$131
- plus $1K from 22 others
What the payments were for
- Food & beverage$4,102100%
- Education$120%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| AbbVie | 43 | $810 |
| AstraZeneca | 25 | $712 |
| Novo Nordisk | 34 | $587 |
| Pfizer | 29 | $425 |
| Lilly USA, LLC | 21 | $350 |
| Exact Sciences | 7 | $131 |
| Salix Pharmaceuticals, A Division Of Bausch Health US, LLC | 6 | $118 |
| Johnson & Johnson | 7 | $118 |
| Amgen | 6 | $107 |
| Abbott | 5 | $87 |
| GSK | 3 | $72 |
| Boehringer Ingelheim | 3 | $67 |
| Merck | 3 | $64 |
| Astellas Pharma US Inc | 2 | $56 |
| Biohaven Pharmaceutical Holding Company Ltd. | 3 | $56 |
| Amarin Pharma, Inc. | 3 | $46 |
| Tolmar, Inc. | 3 | $44 |
| Idorsia Pharmaceuticals US Inc | 2 | $38 |
| Bayer | 2 | $37 |
| Biohaven Pharmaceuticals, Inc. | 2 | $37 |
| Vivus LLC | 2 | $28 |
| Smith+Nephew | 1 | $25 |
| Sumitomo Pharma America, Inc. | 1 | $24 |
| Novartis | 1 | $18 |
| Corcept Therapeutics | 1 | $16 |
| Verity Pharmaceuticals Inc. | 1 | $15 |
| Supernus Pharmaceuticals, Inc. | 1 | $14 |
| Kowa Pharmaceuticals America, Inc. | 1 | $12 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- FARXIGA$225
How this compares
$4,113 in reported general payments places this provider in the 90th percentile of 14,618 family providers in Florida.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| MounjaroTirzepatide | 46 | $70,324 |
| EliquisApixaban | 55 | $55,398 |
| JardianceEmpagliflozin | 40 | $53,358 |
| OzempicSemaglutide | 36 | $46,755 |
| RybelsusSemaglutide | 12 | $23,248 |
| FarxigaDapagliflozin Propanediol | 18 | $22,409 |
| Trelegy ElliptaFluticasone/Umeclidin/Vilanter | 13 | $18,076 |
| VascepaIcosapent Ethyl | 11 | $6,762 |
| Rosuvastatin Calcium | 231 | $3,783 |
| Lantus SolostarInsulin Glargine,hum.Rec.Anlog | 18 | $3,063 |
| Atorvastatin Calcium | 217 | $2,960 |
| Esomeprazole Magnesium | 25 | $2,201 |
| Mometasone Furoate | 14 | $1,978 |
| Gabapentin | 74 | $1,708 |
| Levothyroxine Sodium | 152 | $1,686 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Lilly USA, LLCMounjaro | $350 | $70,32446 claims |
| Novo NordiskOzempic, Rybelsus | $587 | $70,00248 claims |
| PfizerEliquis | $425 | $55,39855 claims |
| Boehringer IngelheimJardiance | $67 | $53,35840 claims |
| AstraZenecaFarxiga | $712 | $22,40918 claims |
| GSKTrelegy Ellipta | $72 | $18,07613 claims |
| AbbVieSynthroid | $810 | $84314 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 14,618 family providers in Florida.
Other family in Clermont
- John HuffakerVenice$8M
- Stephanie MompointMiami$4.5M
- Miguel TrujilloMiami Gardens$4.4M
- Itsel Cardenas RamonMiami$1M
- Lewis HarringtonTampa$954K
- Adam StrosbergFort Lauderdale$859K
- Danielle PharesFt Lauderdale$713K
- David RodriguezHialeah$658K
- Donna OrtizOrlando$417K
- Patrick SzarazMiami$327K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.